Market research
XCUR Exicure Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 3.66
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US30205M3097
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 3.66
About
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XCUR discussion.
5 years, 4 months ago
Exicure, Inc is currently in a long term downtrend where the price is trading 22.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.8.
Exicure, Inc's total revenue sank by 54.8% to $140K since the same quarter in the previous year.
Its net income has dropped by 27.1% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 180.9% to $-12M since the same quarter in the previous year.
Based on the above factors, Exicure, Inc gets an overall score of 1/5.